In the last 90 days, Oric Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 5 sales; 180 institutions reported holding it in 13F filings for Q2 2026, worth $1.34B in total; Viking Global Investors is the only superinvestor holding it.
SEC filings
10-K, 10-Q, 8-K, 20-F and 40-F reports Oric Pharmaceuticals, Inc. filed with the SEC, newest first.
Livermore lists each filing's form, 8-K items and dates only. To read a filing, open it on SEC.gov; an 8-K's press release or other attachments, such as exhibit 99.1 for Item 2.02, are in the filing index.
SEC filings by Oric Pharmaceuticals, Inc.
Filed
Form
8-K items
Period
Document
Filing index
Oct 23, 2026
8-KCurrent report
7.01Item 7.01: Regulation FD disclosure8.01Item 8.01: Other events9.01Item 9.01: Financial statements and exhibits
5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements5.07Item 5.07: Results of a shareholder vote9.01Item 9.01: Financial statements and exhibits
2.02Item 2.02: Results of operations and financial condition (earnings release)2.05Item 2.05: Costs of exit or disposal activities (restructuring)9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement3.02Item 3.02: Unregistered sale of equity securities7.01Item 7.01: Regulation FD disclosure8.01Item 8.01: Other events9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement3.02Item 3.02: Unregistered sale of equity securities7.01Item 7.01: Regulation FD disclosure9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement3.02Item 3.02: Unregistered sale of equity securities7.01Item 7.01: Regulation FD disclosure9.01Item 9.01: Financial statements and exhibits
